Capital Impact Advisors LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Capital Impact Advisors LLC purchased a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) in the 3rd quarter, Holdings Channel reports. The institutional investor purchased 54,960 shares of the company’s stock, valued at approximately $118,000.

Several other large investors also recently modified their holdings of DNA. Bradley Foster & Sargent Inc. CT boosted its position in Ginkgo Bioworks by 7.3% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 74,390 shares of the company’s stock worth $177,000 after acquiring an additional 5,035 shares during the last quarter. IFP Advisors Inc grew its stake in Ginkgo Bioworks by 22.3% during the third quarter. IFP Advisors Inc now owns 81,295 shares of the company’s stock worth $991,000 after buying an additional 14,820 shares in the last quarter. Guild Investment Management Inc. grew its stake in Ginkgo Bioworks by 15.3% during the third quarter. Guild Investment Management Inc. now owns 140,835 shares of the company’s stock worth $439,000 after buying an additional 18,715 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in Ginkgo Bioworks by 307.4% during the third quarter. Canada Pension Plan Investment Board now owns 335,700 shares of the company’s stock worth $1,047,000 after buying an additional 253,300 shares in the last quarter. Finally, AJ Wealth Strategies LLC lifted its holdings in shares of Ginkgo Bioworks by 5.9% in the third quarter. AJ Wealth Strategies LLC now owns 201,200 shares of the company’s stock worth $628,000 after acquiring an additional 11,200 shares during the last quarter. 61.83% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Trading Down 0.8 %

DNA opened at $1.32 on Friday. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $1.19 and a 52 week high of $4.91. The stock has a market cap of $2.56 billion, a PE ratio of -1.02 and a beta of 0.91. The business has a 50 day moving average of $1.66 and a 200-day moving average of $2.15. The company has a quick ratio of 11.67, a current ratio of 11.71 and a debt-to-equity ratio of 0.04.

Wall Street Analysts Forecast Growth

DNA has been the subject of a number of research reports. Berenberg Bank began coverage on shares of Ginkgo Bioworks in a report on Monday, November 28th. They issued a “buy” rating and a $6.00 target price for the company. BTIG Research reduced their price objective on shares of Ginkgo Bioworks from $4.00 to $3.00 in a research note on Sunday, March 5th. Finally, Raymond James cut their price target on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, March 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, Ginkgo Bioworks currently has an average rating of “Hold” and a consensus price target of $4.39.

Insider Activity

In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 29,762 shares of the business’s stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $1.31, for a total value of $38,988.22. Following the sale, the insider now owns 530,736 shares in the company, valued at approximately $695,264.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Mark E. Dmytruk sold 29,762 shares of the company’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $1.31, for a total transaction of $38,988.22. Following the completion of the sale, the insider now directly owns 530,736 shares in the company, valued at approximately $695,264.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Reshma P. Shetty sold 152,094 shares of the business’s stock in a transaction on Friday, January 6th. The shares were sold at an average price of $1.49, for a total transaction of $226,620.06. Following the transaction, the insider now owns 17,453,409 shares of the company’s stock, valued at $26,005,579.41. The disclosure for this sale can be found here. Insiders sold a total of 4,417,242 shares of company stock valued at $7,609,612 in the last 90 days. Company insiders own 17.47% of the company’s stock.

Ginkgo Bioworks Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.